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Introduction
Glucans are mainly found in extracts of some species 
of mushrooms and in certain microbes, such as black 
yeast, and they have several unique immunological 
activities. In particular, β-glucans have been shown to 
activate cytotoxic activity against cancer cells 
accompanied by increased production of interleukin-2 
(IL-2), IL-6, IL-12, interferon-γ (IFN-γ), and tumor 
necrosis factor-α (TNF-α) 1, 2). These findings strongly 
indicate that β-glucans enhance the immune system 
underlying the activation of lymphocytes, monocytes, 
macrophages, granulocytes, and natural killer (NK) 
cells via the β-glucan receptor, Dectin-1 3). 
We established and succeeded in purifying β-1,3-1,6 
glucan (BG) produced by the black yeast Aureobasidium 
pullulans (A. pullulans) strain AFO-202 by using the 
latest culture technology as a health food supplement 
(Sophy β-glucan), which contains about ten-fold the 
quantity of BG in mushroom extracts.  
It has recently been reported that human and animal 
sera contain BG-specific antibodies 4), and we have 
reported finding an immunological relationship 
between BG-spec i f i c ant ibod ies and immune 
biomarkers, including various cytokines and soluble-
form molecules 5). However, the rates of changes or 
kinetics of these BG-specific antibodies and other 
immune biomarkers after consuming Sophy β-glucan 
(main ingredient: BG) as a health food supplement had 
never been investigated. 
In this clinical study we investigated changes in the 
levels of BG-specific antibodies (IgG, IgA2, and IgM) 
and other immune biomarkers, IL-6, soluble-form CD44 
(sCD44), and granulocyte-colony stimulating factor 
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Abstract
   In this clinical study, we investigated changes in the levels of β-1,3-1,6 glucan (BG)-, lipopolysaccharide 
(LPS)-, and ovalbumin (OVA)-specific antibodies (IgG, IgA2, and IgM), interleukin-6 (IL-6), soluble CD44 
(sCD44), and granulocyte-colony stimulating factor (G-CSF) in the sera and saliva of 15 healthy subjects 
after consuming commercially produced Sophy β-glucan (main ingredient: BG) for 1-2 weeks as a health 
food supplement. The results showed significant increases in BG-specific IgG (9.51 ± 4.37%) and IgM 
(16.51 ± 8.87%), but not in BG-specific IgA2. We observed no changes in LPS- and OVA-specific IgG, 
IgA2, or IgM between before and after consumption of the supplement. Clear increases in serum IL-6 
(39.37 ± 16.81%), sCD44 (15.88 ± 8.39%), and G-CSF (15.04 ± 8.43%) were also observed after consuming 
Sophy β-glucan. Increases in IL-6 (8.33 ± 3.82%), BG-IgA2 (11.27 ± 4.63%), and sCD44 (14.12 ± 9.54%) in 
the subjects’ saliva were also observed after consuming Sophy β-glucan for 1 week. Taken together, our 
data suggest that the consumption of Sophy β-glucan clearly enhanced the BG-specific immune network 
system in the whole body.
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(G-CSF), in the sera and saliva of 15 healthy subjects 
after consuming Sophy β-glucan.
Materials and Methods
Reagents
Sophy β-glucan was produced by Sophy Co. (Kochi-
city, Kochi) from A. pullulans strain AFO-202, by using 
the latest biological culture and preparation techniques, 
and it is currently available commercially as a health 
food supplement. The super-purified BG derived from 
Sophy β-glucan described above that was used as an 
antigen in this study was kindly provided by the Sophy 
Co. Enzyme immunoassay (EIA) kits for IL-6 and 
sCD44 were purchased from Diaclone Laboratories Co. 
(USA). An EIA kit for G-CSF was purchased from IBL 
Laboratories Co. (Fujioka, Gunma). Lipopolysaccharide 
(LPS) and ovalbumin (OVA) were purchased from 
Sigma Co. (USA). Horseradish peroxidase (HRPOD)-
conjugated rabbit anti-human IgG, HRPOD-conjugated 
rabbit anti-human IgM and HRPOD-conjugated mouse 
anti-human IgA2 monoclonal antibody (mAb) were 
purchased from MBL Co. (Nagoya). 
Ethics statement
The study protocol was approved by the institutional 
review boards (IRBs) of Kyushu University of Health 
and Welfare and Chikamori Hospital, and the IRB 
numbers were 18-024 and 161, respectively. Informed 
consent was obtained from all of the subjects prior to 
their participation in this study. 
Consumption of Sophy β-glucan as a health 
food supplement and preparation of serum 
and saliva samples
Fifteen healthy subjects with no abnormalities of the 
oral cavity (5 males, age 38.2 ± 9.5 yr; 10 females, age 
28.7 ± 5.2 yr) in Chikamori Hospital (Kochi-city, Kochi) 
consumed Sophy β-glucan, 40 mg/day for 1-2 weeks, as 
a health food supplement. Blood collection and serum 
preparation were performed according to the standard 
methods. To collect saliva, subjects were asked to 
gargle and rinse their mouth (oral cavity) 15 times with 
water, and about 40 min later a saliva specimen was 
collected in a 15-mL sterile tube for 2 min. All serum 
and saliva samples were centrifuged at 3000 rpm for 30 
min, and the supernatants were harvested and stored at 
-80°C until assayed. 
Measurement of BG-, LPS-, and OVA-specific 
antibodies in the serum and saliva samples
EIA plates (Sumitomo Co., Tokyo) were coated with 
1 µg/mL of BG, LPS, and OVA in carbonate bicarbonate 
buffer (0.010 M NaCO3, 0.035 M NaHCO3, pH9.6) for 24 
hr at 4°C. The wells were washed 4 times with 
phosphate-buffered saline (PBS) containing 0.05% 
Tween-20 (PBST) and blocked with PBST containing 
2% BSA (BSA-PBST) for 60 min at room temperature, 
then washed 3 times with PBST. The sera (x1000 
dilution for IgG, x50 dilution for IgA2 and x500 dilution 
for IgM) and the saliva (x5 dilution for IgA2) were then 
added to each well, and the plate was incubated for 60 
min at room temperature with shaking. The wells 
were then washed 5 times with PBST, and after 
adding HRPOD-conjugated rabbit anti-human IgG 
(x10000 dilution), HRPOD-conjugated mouse anti-human 
IgA2 mAb (x3000 dilution), or HRPOD conjugated 
rabbit anti-human IgM (x5000 dilution) to each well, the 
plate was incubated for 60 min at room temperature 
with shaking. The wells were then washed 10 times 
with PBST, and after adding substrate chromogen 
(TMB; Cosmo Bio Co.) to each well, the plate was 
incubated for 20 min at room temperature with gentle 
shaking. The reaction was stopped by the addition of 
0.5 M-HCl, and optical density (O.D.) was read at 450 
nm with a multichannel EIA-microplate reader 
(TOSHO Co.). The experiment was repeated 5 times. 
Measurement of IL-6, sCD44, and G-CSF in 
the serum and saliva samples
The levels of IL-6, sCD44, and G-CSF in the serum 
and saliva samples were measured with EIA kits. Each 
of the measurements was repeated 3 times. 
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Statistical analysis
Data were expressed as the mean ± standard deviation 
(SD). The data were statistically analyzed by performing 
the unpaired t -test. A P value <0.05 was considered 
evidence of a statistically significant difference.
Results and Discussion 
First, we examined the changes in BG-, LPS-, OVA-
specific IgG, IgA2, and IgM and the immune biomarkers 
IL-6, sCD44, and G-CSF in the serum and saliva samples 
of the 15 healthy subjects after consuming Sophy 
β-glucan for 1-2 weeks.
As shown in Figure 1, clear increases in BG-specific 
IgG (9.51 ± 4.37%) and IgM (16.51 ± 8.87%), but not in 
IgA2 (1.12 ± 0.67%), were observed in the sera of the 
healthy subjects after consuming Sophy β-glucan, but no 
changes in LPS- or OVA-specific IgG, IgA2, or IgM were 
seen in their sera under the same conditions. The 
BG-specific IgG and IgM were statistically significant (P 
< 0.01) compared with the percentage increases in LPS-
specific IgG and IgM and OVA-specific IgG and IgM, 
respectively.
Next, we also examined the changes in IL-6, sCD44, 
and G-CSF in the sera after consuming Sophy β-glucan. 
Figure 2 shows that there were marked increases in 
IL-6 (39.37 ± 16.81%), sCD44 (15.88 ± 8.39%), and G-CSF 
(15.04 ± 8.43%) in their sera. We also examined the 
changes in some immune biomarkers in saliva after 
consuming Sophy β-glucan for 1 week, and clear 
increases in IL-6 (8.33 ± 3.82%), sCD44 (14.12 ± 9.54%), 
and BG-IgA2 (11.27 ± 4.63%) were observed. 
In this study increases in BG-specific IgG and IgM 
were observed in the sera after consuming Sophy 
β-glucan in comparison with before consumption, and 
the increases in BG-specific IgM were marked. It is well 
known that IgM is the first antibody to appear as part 
of the immunological response. It may be surmised that 
the increase in BG-specific IgM after consuming 
Sophy β-glucan plays an important role in some 
immunobiological response network. Although we did 
not establish a placebo group in this study because of 
the short period of consumption of Sophy β-glucan, the 
fact that there were no significant increases in LPS-, 
OVA-specific IgG, IgA2, and IgM after consuming 
Sophy β-glucan, suggested that the BG-specific immune 
reaction was effectively appeared in the whole body.    
IL-6 is a cytokine produced by T-cells, B-cells, 
monocytes, fibroblasts, endothelial cells, etc., and plays 
an important role in both natural and acquired immune 
responses, in particularly by regulating the growth and 
maturat ion of B-cel ls to produce ant ibodies 6). 
Interestingly, the results of this study showed increased 
IL-6 in both serum and saliva after consuming Sophy β
-glucan. Thus, it is l ikely that the increases in 
BG-specific IgG and IgM in the sera and BG-specific 
IgA2 in the saliva were directly or indirectly influenced 
by IL-6 action. 
CD44 is expressed on lymphocytes, macrophages, 
granulocytes, fibroblasts, endothelial cells, NK cells, 
etc., and it plays an important role in stimulating 
NK-cell and lymphokine-activated killer cell (LAK) 
functions underlying IFN-γ production. The marked 
increases in sCD44 in both sera and saliva after 
consuming Sophy β-g lucan sugges t tha t the 
enhancement of NK-cell and LAK- cell functions in the 
whole body 7).                                        
G-CSF is a glycoprotein that stimulates the bone 
marrow to produce granulocytes (neutrophils) and 
release them into the bloodstream, and it prolongs the 
survival and st imulates the prol i ferat ion and 
differentiation, and function of neutrophil precursors and 
mature neutrophils 8). In this study we observed an 
increase in G-CSF production in the sera after 
consuming Sophy β-glucan. Sophy β-glucan consumption 
probably stimulates the proliferation and differentiation 
of neutrophils in the immune response and protects 
against microbial infection.                                        
Although the exact mechanism(s) underlying the 
increase and immunological roles of BG-specific 
antibodies and immune biomarkers IL-6, sCD44, and 
G-CSF in the sera and saliva of healthy subjects after 
consuming Sophy β-glucan remains unclear, we are 
vigorously investigating the mechanism(s) by using 
molecular immunological techniques. Since β-glucan has 
been reported to stimulate intestinal immunity 9), it is 
possible that the action of intestinal bacteria flora 
promotes the increase in BG-specific antibodies and 
some immune biomarkers after Sophy β-glucan 
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consumption, and more effectively regulates the 
BG-related immune network system in the whole body 
as a biological response modifier (BRM). Further 
analyses at the cellular and molecular levels in an in 
vitro  model are needed to ident i fy the exact 
mechanism(s) responsible for the increase in BG-specific 
antibodies and some immune biomarkers after 
consuming Sophy β-glucan.
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Figure 1. Measurement of BG-, LPS-, and OVA-specific 
IgG, IgA2 and IgM in the sera of 15 healthy subjects 
after consuming Sophy β-glucan. The measurements 
were performed using an EIA system (See Materials 
and Methods for details). Each measurement was 
repeated 4 times. The percentage increases in each 
subject were calculated as follows. Percent increase 
(%) = {δOD value after consumption - δOD value before 
consumption)/δOD value before consumption} x 100, 
and the average values for the entire population (n = 
15) were then calculated.  
* P < 0.01 (BG-specific IgG vs. LPS-specific IgG or OVA-
specific IgG), ** P < 0.01 (BG-specific IgM vs. LPS-
specific IgM or OVA-specific IgM).
Figure 2. Measurement of IL-6, sCD44, and G-CSF in 
the sera of 15 healthy subjects after consuming Sophy 
β-glucan. The measurements were performed using an 
EIA system (See Materials and Methods for details). 
Each measurement was repeated 4 times. The 
percentage increases in each subject were calculated 
as follows. Percent increase (%) = {amount after 
consumption - amount before consumption)/amount 
before consumption} x 100, and the average values for 
the entire population (n = 15) were then calculated.
Figure 3. Measurement of IL-6, sCD44 and BG-IgA2 in 
the saliva of 15 healthy subjects after consuming 
Sophy β-glucan. The measurements were performed 
using an EIA system (See Materials and Methods for 
details). Each measurement was repeated 4 times. The 
percentage increases in each subject were calculated 
as follows. Percent increase (%) = {amount or δOD value 
after consumption - amount or δOD value before 
consumption)/amount or δOD value before consumption} 
x 100, and the average values for the entire population 
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要旨
　Sophy β-glucan（β-1,3-1,6 glucan）摂取後の健康人血清中および唾液中のβ-1,3-1,6 glucan（BG）特異抗
体と免疫バイオマーカーの動態を酵素抗体法で検討した。その結果、Sophy β-glucan 摂取 2 週間後、摂
取前に対して血清中に BG 特異 IgG(9.51 ± 4.37%) と IgM(16.51 ± 8.87%) の増加が認められた。一方、
lipopolysaccharide (LPS) および ovalbumin (OVA) 特異 IgG、IgA2 および IgM の増加は認められなかった。
さらに、Sophy β-glucan 摂取 2 週間後、摂取前に対して血清中に IL-6(39.37 ± 16.81%)、sCD44(15.88 ±
8.39%)、G-CSF(15.04 ± 8.43%) の増加が認められた。また、Sophy β-glucan 摂取 1 週間後、摂取前に対し
て唾液中に IL-6(8.33 ± 3.82%)、BG-IgA2(11.27 ± 4.63%)、sCD44(14.12 ± 9.54%) の増加が認められた。以
上の結果は、Sophy β-glucan を摂取後、血清中または唾液中の BG 特異 IgG、IgA2 および IgM、さらに
IL-6、sCD44、G-CSF が増加することから BG 特異的な生体免疫システムが増強されたことがわかった。
キーワード ：β-1,3-1,6 glucan(BG)、BG 特異抗体、免疫バイオマーカー、免疫ネットワークシステム
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